Attached files

file filename
EX-99.1 - PRESS RELEASE - MAXYGEN INCd352566dex991.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2012

 

 

Maxygen, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   000-28401   77-0449487
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

411 Borel Avenue, Suite 616

San Mateo, CA 94402

(Address of Principal Executive Offices)

(650) 241-2292

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events

On May 11, 2012, Maxygen, Inc. (the “Company”) received notice from Bayer HealthCare LLC (“Bayer”) that Bayer had achieved the milestone event under the technology transfer agreement between the parties, dated July 1, 2008, pursuant to which the Company will receive a $30.0 million payment from Bayer. A copy of the press release issued by the Company on May 14, 2012 regarding the payment is attached as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

  (d) Exhibits

 

99.1    Press Release dated May 14, 2012, titled “Maxygen to Receive $30 Million Payment from Bayer.”


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MAXYGEN, INC.
  (Registrant)

Date: May 14, 2012

 
 

        /s/ James Sulat

  (Signature)
  Name:     James Sulat
  Title:      Chief Executive Officer